Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study

Evangelos Terpos,Efstathios Kastritis,Evdoxia Hatjiharissi,Eirini Katodritou,Evangelos Eleutherakis Papaiakovou,Evgenia Verrou,Maria Gavriatopoulou,Alexandros Leonidakis,Ioannis Ntanasis-Stathopoulos,Sosana Delimpasi,Marie-Christine Kyrtsonis,Maria Papaioannou,Argiris Symeonidis,Meletios A Dimopoulos

doi:10.1182/blood-2021-152385

Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study

Evangelos Terpos, Efstathios Kastritis + Show 12 more

Open Access

https://doi.org/10.1182/blood-2021-152385

Copy DOI

Journal: Blood

Publication Date: Nov 5, 2021

Affiliation: Datamed Systems Integration (Greece), University of Patras, National and Kapodistrian University of Athens, Theageneio General Hospital, Aristotle University of Thessaloniki, Evangelismos Hospital

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study

Full Text